David Baltimore

David Baltimore's record is short, 17 filings published from March 31, 2016 to June 27, 2025, and spread over three companies where the listed title is Director: Regulus Therapeutics Inc. (9 filings), Amgen Inc (7) and Immune Design Corp. (1).

Market trades are few: a purchase of EUR 19,939 at Regulus on January 30, 2025, or 33% of market trades, and 2 sales at Amgen worth EUR 965,060 in total, of EUR 506,550 on May 31, 2017 and EUR 458,510 on April 29, 2016. The record also holds 8 grants, 5 filings of another nature and one option exercise.

The calendar is distinctive: 4 filings in 2016, 3 in 2017, 2 in 2018, 1 in 2019, then 7 in 2025. No filing falls in the last twelve months, the latest dating from June 2025. The median publication delay is 2 days.

Four colleagues each have one trade within 30 days of Baltimore's and in the same direction: Cynthia M. Patton, Joseph P. Hagan, Madhavan Balachandran and Sean E. Harper. For Christopher Ray Aker, the close trade goes the other way.